1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-10 am EDT
1556.60 GBX   -5.48%
11:02aEuropean ADRs Climb Higher in Wednesday Trading
MT
05:05aExclusive-Rotavirus childhood vaccine shortage hits four African countries
RE
04:59aExclusive-Rotavirus childhood vaccine shortage hits four African countries
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
1658.4(c) 1667(c) 1659.4(c) 1646.8(c) 1556.6 Last
4 413 895 3 917 789 3 254 908 5 624 487 12 919 214 Volume
-1.10% +0.52% -0.46% -0.76% -5.48% Change
More quotes
Estimated financial data (e)
Sales 2022 29 863 M 36 095 M 36 095 M
Net income 2022 4 410 M 5 330 M 5 330 M
Net Debt 2022 15 314 M 18 510 M 18 510 M
P/E ratio 2022 15,2x
Yield 2022 3,48%
Sales 2023 30 498 M 36 863 M 36 863 M
Net income 2023 5 020 M 6 067 M 6 067 M
Net Debt 2023 12 012 M 14 519 M 14 519 M
P/E ratio 2023 13,2x
Yield 2023 3,47%
Capitalization 66 668 M 80 582 M 80 582 M
EV / Sales 2022 2,75x
EV / Sales 2023 2,58x
Nbr of Employees 90 096
Free-Float 93,6%
More Financials
Company
GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also... 
More about the company
Ratings of GSK plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GSK PLC
11:02aEuropean ADRs Climb Higher in Wednesday Trading
MT
05:05aExclusive-Rotavirus childhood vaccine shortage hits four African countries
RE
04:59aExclusive-Rotavirus childhood vaccine shortage hits four African countries
RE
04:24aViiV Healthcare Announces Support for Community-Based Organizations With New Monkeypox ..
AQ
04:22aExclusive-Rotavirus childhood vaccine shortage hits four African countries
RE
08/08Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Com..
AQ
08/08GlaxoSmithKline, IQVIA Introduce Vaccination Data Tracker
MT
08/08GSK plc and IQVIA launch Vaccine Track
CI
08/08ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help imp..
BU
08/08UBS Keeps GSK At Neutral, Trims PT
MT
08/08GSK : Ubs cuts target price to 1820p from 1860p…
RE
08/08Climate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
08/05UK Financial Watchdog Fines Ex-ConvaTec Chair For Sharing Inside Information
MT
08/05GSK : Morgan stanley resumes coverage with equal weight; target p…
RE
08/03European ADRs Nudge Higher in Wednesday Trading
MT
More news
News in other languages on GSK PLC
11:02aLes ADR européens montent en flèche dans les échanges de mercredi
05:05aExclusif-La pénurie de vaccins infantiles contre le rotavirus frappe quatre pays africa..
04:59aExclusif-La pénurie de vaccins infantiles contre le rotavirus frappe quatre pays africa..
04:22aExclusif-La pénurie de vaccins infantiles contre le rotavirus frappe quatre pays africa..
08/08GlaxoSmithKline et IQVIA lancent un outil de suivi des données de vaccination
More news
Analyst Recommendations on GSK PLC
More recommendations
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 646,80 GBX
Average target price 2 038,46 GBX
Spread / Average Target 23,8%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC0.20%80 582
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
PFIZER, INC.-16.05%279 310
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976